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Introduction: Noninvasive ventilation (NIV) is a well-established treatment for acute-
  on-chronic respiratory failure in hypercapnic COPD patients. Less is known about the effects 
of a long-term treatment with NIV in hypercapnic COPD patients and about the factors that may 
predict response in terms of improved oxygenation and lowered CO2 retention.
Methods: In this study, we randomized 15 patients to a routine pharmacological treatment 
(n = 5, age 66 [standard deviation ± 6] years, FEV1 30.5 [±5.1] %pred, PaO2 65 [±6] mmHg, 
PaCO2 52.4 [±6.0] mmHg) or to a routine treatment and NIV (using the Synchrony BiPAP device 
[Respironics, Inc, Murrsville, PA]) (n = 10, age 65 [±7] years, FEV1 29.5 [±9.0] %pred, PaO2 
59 [±13] mmHg, PaCO2 55.4 [±7.7] mmHg) for 6 months. We looked at arterial blood gasses, 
lung function parameters and performed a low-dose computed tomography of the thorax, which 
was later used for segmentation (providing lobe and airway volumes, iVlobe and iVaw) and 
post-processing with computer methods (providing airway resistance, iRaw) giving overall a 
functional image of the separate airways and lobes.
Results: In both groups there was a nonsignificant change in FEV1 (NIV group 29.5 [9.0] to 
38.5 [14.6] %pred, control group 30.5 [5.1] to 36.8 [8.7] mmHg). PaCO2 dropped significantly 
only in the NIV group (NIV: 55.4 [7.7] → 44.5 [4.70], P = 0.0076; control: 52.4 [6.0] → 47.6 
[8.2], NS). Patients actively treated with NIV developed a more inhomogeneous redistribution 
of mass flow than control patients. Subsequent analysis indicated that in NIV-treated patients 
that improve their blood gases, mass flow was also redistributed towards areas with higher 
vessel density and less emphysema, indicating that flow was redistributed towards areas with 
better perfusion. There was a highly significant correlation between the % increase in mass 
flow towards lobes with a blood vessel density of .9% and the increase in PaO2. Improved 
ventilation–perfusion match and recruitment of previously occluded small airways can explain 
the improvement in blood gases.
Conclusion: We can conclude that in hypercapnic COPD patients treated with long-term NIV 
over 6 months, a mass flow redistribution occurs, providing a better ventilation–perfusion match 
and hence better blood gases and lung function. Control patients improve homogeneously in 
iVaw and iRaw, without improvement in gas exchange since there is no improved ventilation/
perfusion ratio or increased alveolar ventilation. These differences in response can be detected 
through functional imaging, which gives a more detailed report on regional lung volumes and 
resistances than classical lung function tests do. Possibly only patients with localized small 
airway disease are good candidates for long-term NIV treatment. To confirm this and to see if 
better arterial blood gases also lead to better health related quality of life and longer survival, 
we have to study a larger population.
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Introduction
COPD is now the fourth leading cause of death in the world.1 
Patients with severe COPD (FEV1 ,50%) often develop 
chronic hypercapnic respiratory failure. Their prognosis 
worsens and they are more likely to develop exacerbations.2 
This has a big influence on their health-related quality of 
life (HRQOL).3
Until now, only few interventions diminish the   number 
of exacerbations and improve survival significantly. 
  Long-acting beta-antagonists and inhaled corticosteroids, 
as well as pulmonary rehabilitation programs, do influence 
the number of exacerbations. Long-term oxygen therapy 
(LTOT) and volume reduction surgery improve survival in 
well-selected patients.4
In hypercapnic patients, noninvasive ventilation (NIV) is 
often added to the treatment. This can improve gas exchange, 
unloads the respiratory muscles, and resets the central 
respiratory drive. It has been shown that NIV in acute settings 
can prevent intubation and invasive ventilation, and reduces 
hospital mortality.5, 6 Nevertheless, there is still little information 
about NIV given on a long-term basis: it remains unclear how 
long these patients should be ventilated and what the effect 
could be.7–11 A recent study showed that COPD patients who 
remain hypercapnic after acute respiratory failure requiring 
mechanical ventilation may benefit from long-term NIV .12
Recent randomized studies show a positive effect of long-
term (months) ventilation on CO2 retention and HRQOL in 
stable hypercapnic (PaCO2 .50 mmHg) patients on LTOT.2 
It was also shown that stable, severe chronic hypercapnic 
patients who were treated with NIV at high inspiratory 
  pressures had a better survival than patients who did not 
receive NIV: 1- and 2-year survival of 87.7% and 71.8% with 
NIV vs 56.7% and 42% without NIV . Patients displaying 
more severe disease according to known risk factors seemed 
to benefit most from long-term NIV .13 Exercise capacity 
would improve and intensive care unit admissions would 
diminish when using chronic NIV with LTOT vs LTOT alone 
in stable COPD with chronic hypercapnia. All studies took 
place in patients who were stable at that time.
No information is available about the success of NIV 
continued at home in patients who needed NIV in an acute 
  setting. In many European countries including Belgium, NIV 
is not a standard treatment in chronic hypercapnic COPD, 
and therefore not reimbursed in this case, which is another 
reason why it is important to prove that chronic NIV can have 
beneficial effects in hypercapnic COPD.
Until now, only a few outcome parameters have been used 
in evaluating COPD patients: the measuring of static and 
dynamic lung volumes and arterial blood gases gives us an 
idea about the lung as such without regional information. 
A new method for measuring lung function is functional 
imaging: with this method regional airway resistance and 
compliance can be measured by computed tomography 
(CT)-based computational fluid dynamics (CFD).14–20 This 
method can detect regional differences in both parameters and 
may reveal still unknown effects of NIV in smaller parts of 
the lung. The course of the disease may become clearer this 
way. An improvement in HRQOL can possibly be explained 
by regional changes in the airways, which can be detected 
with this method.
Despite lack of evidence, NIV in stable hypercapnic 
COPD is rated as beneficial and frequently used.21 An 
explanation for this phenomenon must be looked for.
Is the clue to success the more aggressive form of 
ventilation as applied by Windisch et al,22 where high 
inspiratory pressures and high breathing frequency are 
applied in a pressure-controlled methods? It is clear that 
NIV may improve the alveolar ventilation in a sustained 
way, since PaCO2 often decreases also during daytime when 
no NIV is applied.23
But perhaps there are just different responder groups 
among COPD patients. We know that NIV which is 
  insufficient to lower PaCO2 does not improve clinical outcome 
in stable hypercapnic COPD. And NIV that can improve 
physiological parameters might have the potential to improve 
HRQOL and survival.
The aim of this study therefore was to use extended 
disease descriptors to select and follow hypercapnic COPD 
patients admitted with acute-on-chronic respiratory failure. 
Those patients will be treated with supplemental NIV or 
with routine pharmacological treatment without NIV. We 
aimed to answer the question: Why is there a decrease of 
daytime PaCO2 and an increase in daytime PaO2 (and hence 
an improved HRQOL and survival) only in some COPD 
patients treated with long-term NIV?
Materials and methods
Patients after acute hypercapnic COPD exacerbations (treated 
with NIV in the acute phase) were followed over time in a 
controlled way using several endpoints. Primary outcome 
variables were arterial blood gas values and functional 
imaging of the lungs. Secondary outcome variables were lung 
function tests (static and dynamic lung volumes, diffusion) 
and exercise tolerance.
It was a parallel group, randomized, controlled study, 
prospective with an interventional component (NIV). 
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COPD patients GOLD stages III and IV (FEV1 ,50%, 
Tiffeneau ,70%) who were hospitalized in the University 
Hospital of Antwerp (Department of Respiratory Medicine) 
due to an exacerbation and developed persisting hypercapnia 
(PaCO2 .45 mmHg) on days 5–12, despite maximal phar-
macological treatment, were randomized into two groups: 
maximal pharmacological treatment (n = 5) vs maximal phar-
macological treatment + NIV during 6 months (n = 10).
NIV was supplied with a Synchrony BiPAP device 
(Respironics, Inc, Murrsville, PA), for .5 hours a day, with 
full face mask, starting 5–12 days after admission. Modes 
were adapted until O2 saturation was .90% during 90% of 
the time and PaCO2 was decreased 5% in 1 hour. Patients were 
ventilated during at least 6 months, and were in follow-up 
for 1 year.
These patients were re-evaluated at 1, 3, and 6 months by 
arterial blood gases and pulmonary function tests. CT scan 
of the thorax was taken at the start of the study and after 
6 months. The NIV device was checked and analyzed on 
every visit. Hospital admissions, morbidity, and mortality 
were kept in the file.
Patients were included if they were 18–80 years of age, 
COPD GOLD III or IV (FEV1 ,50%, Tiffeneau ,70%), 
hospitalized due to an exacerbation, and had persisting 
hypercapnia (PaCO2 .45 mmHg) on day 5–12 under maximal 
pharmacological treatment. They must have stopped smoking 
and must not have had any treatment with home NIV before 
admission. Patients who were invasively ventilated, asthmatic 
patients, patients with restrictive lung diseases, malignancy, 
heart failure, or obstructive sleep apnea syndrome were 
excluded from the study.
All patients underwent a history and physical examina-
tion at every visit. Between days 5 and 12, arterial blood 
gases were taken before starting with NIV . Blood gases were 
repeated after 1, 3, 6, and 12 months. Between day 5 and 12, 
lung function tests (spirometry + reversibility, body plethys-
mography including functional residual capacity (FRC) and 
airway resistance [Raw], specific airway resistance [sRaw] 
measurements, diffusion capacity (diffusing capacity of the 
lung for CO, DCLCO) maximum inspiratory pressure [MIP], 
maximum expiratory pressure [MEP], 6-minute walking 
distance [6MWD]) were measured, and were repeated after 
1, 3, and 6 months. Also, between day 5 and 12 and repeated 
after 6 and 12 months, CT scan was performed with a low 
radiation protocol. These images are made to perform CFD 
(by FluidDA, Kontich, Belgium) on in order to obtain more 
information on regional lung function characteristics. Hospital 
admissions and morbidity/mortality was registered, as well as 
compliance (memory card Synchrony device and history). The 
approval of the local ethical committee was obtained.
CT and segmentation14–20
At each CT data collection time point two thorax CT scans 
were taken on a 64-slice GE LightSpeed VCT scanner. One 
scan was taken at total lung capacity (TLC), the other at FRC. 
The lung volumes were controlled during the CT   procedure 
using adapted spirometry. Scans were taken in a dose 
reduction protocol, ie, reduced tube voltage (100 kV) and 
tube current as function of the patients’ weight (1 mAs/kg). 
In addition to this, there was an increase in noise factor to 
further reduce the radiation dose. Total radiation dose for 
the CT scans taken in this study per patient was ,12 mSv. 
Scanning time was ,5 seconds per scan, voxel dimension 
was ≈0.5 mm3, and the scanning region extended from the 
larynx down to the diaphragm.
CT images
Segmentation
– Voxel thresholding
– Mask operations
3D reconstruction
– Staircasing effect
– Highly skewed elements
Post processing
– Smoothing with volume reduction
   compensation
– Remeshing to reduce triangle skew
– Dynamic region growing
  algorithms
Figure 1 Functional imaging derived from a high resolution computed tomography scan.
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From the CT data a 3D reconstruction of the airway 
geometries at TLC was performed by a semi-automatic 
  segmentation of the airways up to the point where no 
  distinction could be made between the intraluminal 
and   alveolar air (fifth to seventh bifurcation, airway 
  diameter ≈1 mm). In addition the lung lobes were segmented 
both at TLC and FRC by identifying the fissure planes and 
subsequently using these surfaces as cutting objects. By 
segmenting the lung lobes at two lung levels it was possible 
to assess the lobar expansion and hence the internal patient 
specific mass flow distribution in the lower airways. The 
segmentation and 3D model reconstruction was performed 
with a commercially developed and validated software pack-
age (Mimics, Materialise, Belgium). To determine the local 
change in airway volume, the models were subdivided in 
individual branches according to the nomenclature as defined 
by Ikeda (as described by Netter24). For each individual air-
way branch the airway volume (iVaw) was then determined 
before and after the study intervention. For each lobe also 
the volumetric fraction occupied by blood vessels, ie, blood 
vessel density, was calculated from the CT scan images by 
taking the percentage of voxels in a lobe that lie in the [-600, 
600] HU range (Figure 1).
Computational fluid dynamics
Subsequently the 3D models were converted in a computational 
grid using a commercial software package (T-Grid, Fluent 
Inc, USA). Mesh size was around 4.5 × 106 cells. Steady 
flow simulations on these grids were performed using a 
commercial CFD solver (Fluent, Fluent Inc, New York, NY).   
A mass flow of 30 L/min was specified as boundary condition 
at the trachea to reflect normal tidal breathing. At the outlets 
the static pressure was defined using an iterative process 
to reflect the internal mass flow distribution matching the 
lobar expansion as derived from the CT data. The flow was 
considered   laminar, incompressible, and adiabatic. Detailed 
descriptions of the segmentation and flow simulation 
procedures can be found in De Backer et al.25
From the CFD data the local airway resistance (iRaw) 
was obtained. iRaw was defined as:
iRaw =
∆p
F
,
where ∆p equals the total pressure drop over a certain region 
and F equals the mass flow rate of air through this region.
Statistics
Variables are presented as mean and standard deviation 
(SD) for normally distributed variables and as median and 
range for not normally distributed variables. Differences 
over time were assessed using Wilcoxon matched pairs test. 
Correlations were calculated with Spearman correlation 
analysis. A P value , 0.05 was considered as statistically 
significant. All analyses were performed using SPSS 17.0.
Results
Descriptive data are given in Table 1. Fifteen hypercapnic 
COPD patients were enrolled, five females and ten males, 
with a mean age of 65 years and a mean FEV1 of 29%pred.
Data on blood gases (PaO2) and percentage of lobar 
mass flow and iRaw are given in Figures 2–5 for both 
groups and individual patients. In both groups there was a 
nonsignificant change in FEV1 (NIV group 29.5 [standard 
deviation (SD) ±9.0] to 38.5 [SD ± 14.6] %pred; control 
group 30.5 [SD ± 5.1] to 36.8 [SD ± 8.7] mmHg). PaCO2 
dropped significantly only in the NIV group (NIV: 55.4 
Table 1 Baseline measurements for all patients enrolled
  N Range Minimum Maximum Mean SD
Age (years) 15 24 52 76 65.60 6854
Pao2 (mmHg) 15 43 43 86 61.73 11,298
Paco 2 (mmHg) 15 24 45 69 54.40 7169
FEV1 (%pred) 15 27 20 47 29.80 7757
VC (%pred) 15 65 38 103 64.53 15,950
Tiffeneau 15 29 23 52 36.00 8358
RV (%pred) 15 196 127 323 193.47 54,181
TLC (%pred) 15 61 90 151 110.80 18,899
FRC (%pred) 15 128 121 249 159.13 37,403
Spec R 15 10,600 3620 14,220 6866.87 3080.323
DLCO/VA (%pred) 11 45 42 87 62.64 17.218
MIP (%pred) 12 77 55 132 77.58 22.476
MEP (%pred) 12 109 48 157 87.17 34.803
Abbreviations: VA, alveolar volume; VC, vital capacity; RV, residual volume; TLC, total lung capacity; DLCO, diffusion capacity; MEP, maximum expiratory pressure;   
MIP, maximum inspiratory pressure; SD, standard deviation.
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Figure 2 Mass flow (re)distribution (left) and change in airway resistance per lobe (right) in a patient treated with noninvasive ventilation for 6 months.
Abbreviations: RUL, right upper lobe; RML, right middle lobe; RLL, right lower lobe; LUL, left upper lobe; LLL, left lower lobe.
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Figure 3 Mass flow (re)distribution (left graph) and change in airway resistance per lobe (right graph) in a patient not treated with noninvasive ventilation for 6 months.
Abbreviations: RUL, right upper lobe; RML, right middle lobe; RLL, right lower lobe; LUL, left upper lobe; LLL, left lower lobe.
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[SD ± 7.7] → 44.5 [SD ± 4.70], P = 0.0076; control group: 
52.4 [SD ± 6.0] → 47.6 [SD ± 8.2], NS). The 6-minute 
walking distance increased significantly in the NIV group 
(232 ± 151 m to 282 ± 146 m, P = 0.01), while there was 
no change in the control group (408 ± 34 m to 401 ± 78 m, 
P = 0.085). There were no significant changes either in the 
active or the control group for MIP, MEP, FRC, TLC, Raw, 
sRaw, and DLCO.
Patients actively treated with NIV developed a more 
inhomogeneous redistribution of mass flow than control 
patients (Figure 6). Subsequent analysis indicated that in NIV-
treated patients who improved their blood gases, mass flow 
was redistributed towards areas with higher   vessel density 
and less emphysema, indicating that flow was   redistributed 
towards areas with better perfusion. There was a highly sig-
nificant correlation between the percentage increase in mass 
 Mean 
 ± SE 
 ± SD  PaO2 baseline
PaO2 6 months
45
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65
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80
P = 0.046
P
a
O
2
Figure 4 Changes in PaO2 (mmHg) in COPD patients treated with noninvasive ventilation for 6 months.
Abbreviations: SE, standard error; SD, standard deviation.
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Figure 5 Changes in PaO2 (mmHg) in COPD patients treated without noninvasive ventilation (controls).
Abbreviations: SE, standard error; SD, standard deviation; NS, not significant.
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flow towards lobes with a blood vessel density of .9% and 
the increase in PaO2 (Figure 7). This phenomenon can explain 
the increase in oxygenation seen in the NIV group as a conse-
quence of improved ventilation–perfusion (V/Q) match. The 
lowering of the PaCO2 in the NIV group (PaCO2 at baseline 
55.4 mmHg, PaCO2 after 6 months of NIV 44.5 mmHg, dif-
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Figure 6 Internal mass flow redistribution was bigger in noninvasive ventilation (NIV)-
treated patients than in controls.
Notes: Imaging showed higher internal mass flow redistribution in NIV-treated patients: 
better V/Q matching due to airflow redistribution in NIV-treated patients.
ference 10.9 mmHg, P = 0.007) can be explained by increased 
alveolar ventilation by recruitment of the previously occluded 
peripheral, small airways.
Discussion
In this study we could observe that COPD patients remaining 
chronic hypercapnic after an acute exacerbation can be treated 
effectively with sustained NIV . They can improve their blood 
gases, both hypoxia and hypercapnia, and we hypothesize 
that patients with localized emphysema (V/Q mismatch) can 
achieve this improvement because mass flow is redistributed, 
with more airflow towards better functioning parts of 
the lung with preserved blood flow. This then results in a 
better V/Q match with improved blood gases and improved 
exercise capacity. We stated that in the past26 pulmonary 
function tests, arterial blood gases, and questionnaires were 
not able to predict response. Using functional imaging we 
can predict that there will be a redistribution of mass flow 
when there are lobes with a blood vessel density .9%. When 
air is redistributed towards better functioning lobes, blood 
gasses (PaO2) will improve. This has to be confirmed in a 
larger population. Patients without lobes with a blood vessel 
density .9% have no chance of redistributing air towards 
better functioning parts, because there are none. So these are 
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Figure 7 Correlation between redistribution of mass flow towards well-perfused lung zones (>9% blood flow) and PaO2 in COPD patients treated for 6 months with noninvasive 
ventilation.
Notes: r = 0.95, P < 0.05 (Spearman Rank).
Abbreviation: MF, mass flow.
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probably worse candidates for long-term NIV . But this also 
has to be confirmed in a larger population.
Imaging, combined with segmentation (and CFD), 
shows indeed a remodeling with a redistribution of airflow 
in some patients, towards better functioning lobes. When we 
take a closer look and apply CT/CFD to count/calculate the 
percentage of active blood vessels throughout the different 
lobes, we can see that air is driven towards lobes with a 
better V/Q match.
So, from this pilot study, we can suspect that if a stable 
hypercapnic COPD patient has localized emphysema and 
still also well-preserved lung areas, the patient is probably a 
good candidate for long-term NIV .
COPD patients are widely treated with NIV according to 
the Eurovent study, even without convincing evidence, so 
there must be some evidence-based arguments for this so far 
experience-based therapy.
A lot of research has been done in this field with 
  conflicting results. Findings were improvement in arterial 
blood gases, HRQOL, reduced need for hospitalization, 
reduced dyspnea, and improvement in exercise capacity.26 
But these findings were not very consistent and were not 
confirmed in other studies. A recent large Australian study 
found improved survival, but poorer general and mental 
health in NIV-treated patients.27
Most studies have focused on clinical outcomes such as 
improved exercise capacity,28,29 and arterial blood gas and 
lung function tests.22,30 Few studies have also focused on 
HRQOL,31–33 which was improved in NIV-treated COPD 
patients. And in patients with severe disability due to chronic 
disease, HRQOL may be more important than prolonga-
tion of life or improvement in physiologic outcomes.
Conflicting results have been the main findings to date. 
In stable COPD, NIV does not affect the natural course of 
the disease34. NIV in COPD patients is questionable, contro-
versial, and not definitely proved.35 Other factors than those 
studied until now therefore must play a role in beneficial 
effects on gas exchange36 and it is suspected that there might 
be a subgroup that responds well to NIV .37
To date no real physiological theories have pointed to 
the mechanism of NIV in COPD. This however is crucial 
to determine the right endpoints needed to evaluate the 
treatment in these patients.26 Nickol et al38 found a higher 
  ventilatory response to CO2 and Diaz et al39 explained the 
success of NIV by less lung hyperinflation and less inspira-
tory load. Others suggested that the resting of the respiratory 
muscles causes the effect of NIV . But these hypotheses do not 
explain the entire mechanism of NIV . Why is it, for example, 
that higher pressures22,40 have better results in COPD patients? 
There must be a mechanical explanation.
This study started from a different point of view: instead 
of focusing primarily on clinical outcome, the focus was on 
a possible mechanism for explaining the treatment, which 
makes treatment modes and candidates easier to find, because 
of the physiological foundation.
By studying the different parts of the lungs, regional 
effects and shifts of mass flow become clear. Previous 
techniques, such as classical lung function tests and arterial 
blood gases, give some idea about the lungs as a whole, but no 
differences can be detected between the effects on different 
parts of the lung. Functional imaging is the first technique 
to do so. This is the reason why these mechanisms were not 
discovered before, and could be a clue about the effect of 
NIV in COPD.
It seems that there is a mechanical effect of blowing 
air into the lungs over a longer period and that airway 
recruitment takes place with a beneficial outcome. After a 
certain period (we do not know for how long, but definitely 
after 6 months) air goes to better perfused areas, resulting in 
more efficient gas exchange.
From the results of this study, we can conclude that 
pulmonary function tests and arterial blood gases, were not 
enough to predict which patients are the right candidates for 
the treatment.
We looked at airway and lobe specifics with a new 
technology that makes it possible to calculate regional 
differences in airway volume, lobe volume, and airway 
resistance. With this method, we can look at each airway 
and each lobe separately.
The study could be criticized for starting treatment at 
the end of an exacerbation and comparing an outcome a few 
months later in a stable situation. However, we studied a real 
life situation, which is more useful for application to clinical 
practice. One week after the start of the exacerbation, lung 
function tests and arterial blood gasses can reach a less critical 
level, what makes it reasonable to start from this point. In 
real life it is also exactly at this point that the physician has 
to decide whether or not to continue NIV at home. Because 
of the small sample size, randomization cannot guarantee 
the balance of the distribution of confounders between the 
two groups.
We can conclude from these study results that chronic 
hypercapnic COPD patients who respond to long-term 
NIV have the capability to recruit peripheral airways and 
increase their alveolar ventilation in well-preserved lung 
zones in a sustained way. It remains to be determined 
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whether this recruitment occurs very early in the course of 
the NIV treatment and whether early evaluation of the flow 
redistribution can help us to select the patients who merit 
continued treatment. The overall response to NIV was good, 
but when we look at each patient separately, we can see that 
the response can be worse according to our hypothesis: less 
localized emphysema gives less possibility for improving 
V/Q mismatch and arterial blood gasses.
Finally the relationship between the level of applied 
(inspiratory) pressure and the peripheral/small airway 
recruitment is yet to be determined, as is the sustainability 
of the obtained changes after interruption of NIV treatment. 
So although many more questions have to be answered, the 
method we used in this preliminary study can further be used 
in studies addressing these remaining questions.
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